 |
 |
 |
 |
 |
||||||||||||||
Benign Prostate Hyperplasia A Phase III clinical trial to assess the safety and long-term efficacy of NX-1207 in patients with symptomatic Benign Prostate Hyperplasia Why This Trial Is Important Benign Prostate Hyperplasia (BPH) is the most common neoplastic disease occurring in men over the age of 45. It is more common in older men. Forty percent of men report moderate or severe urinary symptoms by age 40 to 80.
The symptoms of BPH include a hesitant, interrupted and/or weak urinary stream; leaking or dribbling; and frequent urination, particularly at night. These symptoms stem from obstruction of the urethra (caused by enlarged prostate) and gradual loss of bladder functions that result in incomplete emptying.
Current treatments include the use of herbal supplements, drug treatment with alpha blockers and/or 5-alpha reductase inhibitors, invasive non-surgical treatments such as microwave induced hyperthermia, and surgical treatment by transurethral resection (TURP).
NX-1207 is an experimental drug which means that it is still at the research stage and has not been cleared for marketing by the FDA, the agency who decides which medications should be sold to the public. There have been 2 previous studies with this compound in patients with symptomatic BPH. Who Can Join This Trial? Men aged 45 or older with Benign Prostate Hyperplasia may be eligible to enroll in this study. Please contact us for a complete list of inclusion/exclusion criteria or to schedule a screening appointment. Study Site and Contact Information Southeastern Research Group, Inc. Please contact us if you are interested in participating in this study. |
|
|||||||||||||||
 |
 |
